Silence Therapeutics PLC logo

Silence Therapeutics PLC

OTCPK:SLNCF (UK)  
$ 7.60 0 (0%) 11:09 PM EST
At Loss
P/B:
6.74
Enterprise V:
$ 866.67M
Volume:
-
Avg Vol (2M):
2.06K
Trade In:
Volume:
-
At Loss
Avg Vol (2M):
2.06K

Business Description

Description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
Name Current Vs Industry Vs History
Cash-To-Debt 551.41
Equity-to-Asset 0.64
Debt-to-EBITDA -0.01
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.42
Distress
Grey
Safe
Beneish M-Score -2.04
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 43.94
9-Day RSI 47.82
14-Day RSI 49.33
6-1 Month Momentum % 333.33
12-1 Month Momentum % 639.52

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.82
Quick Ratio 12.82
Cash Ratio 10.78
Days Sales Outstanding 63.03
Days Payable 455.61

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.6
Shareholder Yield % -16.36

Financials (Next Earnings Date:2024-08-16 Est.)

SLNCF's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:SLNCF

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Silence Therapeutics PLC Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 33.379
EPS (TTM) ($) -0.389
Beta 0.87
Volatility % 215.1
14-Day RSI 49.33
14-Day ATR ($) 1.059407
20-Day SMA ($) 7.7625
12-1 Month Momentum % 639.52
52-Week Range ($) 0.6 - 14.75
Shares Outstanding (Mil) 139.98

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Silence Therapeutics PLC Filings

Filing Date Document Date Form
No Filing Data

Silence Therapeutics PLC Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Silence Therapeutics PLC Frequently Asked Questions

What is Silence Therapeutics PLC(SLNCF)'s stock price today?
The current price of SLNCF is $7.60. The 52 week high of SLNCF is $14.75 and 52 week low is $0.60.
When is next earnings date of Silence Therapeutics PLC(SLNCF)?
The next earnings date of Silence Therapeutics PLC(SLNCF) is 2024-08-16 Est..
Does Silence Therapeutics PLC(SLNCF) pay dividends? If so, how much?
Silence Therapeutics PLC(SLNCF) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1